Braj News Magazine

Cytomegalovirus Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Cytomegalovirus Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 17
17:40 2023
Cytomegalovirus Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
DelveInsight’s ‘Cytomegalovirus Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Cytomegalovirus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytomegalovirus pipeline domain.

DelveInsight’s Cytomegalovirus Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Cytomegalovirus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cytomegalovirus pipeline domain.

Key Takeaways from the Cytomegalovirus Pipeline Report

  • Over 20+ Cytomegalovirus pipeline therapies are in various stages of development, and their anticipated acceptance in the Cytomegalovirus market would significantly increase market revenue. 
  • Leading Cytomegalovirus companies developing novel drug candidates to improve the Cytomegalovirus treatment landscape include Moderna, and others.
  • Promising Cytomegalovirus pipeline therapies in various stages of development include mRNA-1647,and others.

Cytomegalovirus Overview

Cytomegalovirus (CMV) is a wide-spread virus, with manifestations ranging from asymptomatic to severe end-organ dysfunction in immunocompromised patients with congenital CMV disease. Human cytomegalovirus is a member of the viral family known as herpesviruses, Herpesviridae, or human herpesvirus-5 (HHV-5). Human cytomegalovirus infections commonly are associated with the salivary glands. CMV infection may be asymptomatic in healthy people, but they can be life-threatening in an immunocompromised patient.

Cytomegalovirus Pipeline Analysis: Drug Profile

mRNA-1647: Moderna

mRNA-1647 includes six mRNAs encoding two antigens in one vaccine and is developed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex, and one mRNA encodes the glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is vital for CMV entry into most cells, including epithelial cells, while gB is essential for entry into all susceptible cells, including fibroblasts. A vaccine that develops an immune response against both pentamer and gB can prohibit CMV entry into a range of target cell types and thus inhibit primary and congenital infections.

Discover more about the emerging Cytomegalovirus drugs @ Cytomegalovirus Treatment Drugs

Cytomegalovirus Key Companies

  • Moderna
  • Nacuity Pharmaceuticals

Cytomegalovirus Pipeline Therapies

  • mRNA-1647
  • NP-3

Cytomegalovirus Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Cytomegalovirus Pipeline Report 

  • Coverage: Global 
  • Key Cytomegalovirus Companies: Moderna, and others
  • Key Cytomegalovirus Pipeline Therapies: mRNA-1647, and others

Find out more about the Cytomegalovirus treatment options in development @ Cytomegalovirus Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the cytomegalovirus pipeline segment

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/